Teva Ticlopidine Court Dismissal Not Properly Reviewed By FDA - D.C. Court
Executive Summary
The dismissal of Teva's ticlopidine patent declaratory judgement action by a California district court was not properly reviewed by FDA as a trigger of 180-day generic market exclusivity, Washington, D.C. district court ruled Aug. 19.